CYRAMZA (Ramucirumab)
CYRAMZA (Ramucirumab)
  • Load image into Gallery viewer, CYRAMZA (Ramucirumab)
  • Load image into Gallery viewer, CYRAMZA (Ramucirumab)

CYRAMZA (Ramucirumab)

Regular price
$769.99 USD
Sale price
$769.99 USD
Regular price
Sold out
Unit price
Shipping calculated at checkout.

prescription refrigerated

What is this medication?

CYRAMZA (Ramucirumab)
Antineoplastic Agent, Monoclonal AntibodyVascular Endothelial Growth Factor (VEGF) Inhibitor; Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor

CYRAMZA (Ramucirumab) is indicated for the treatment of metastatic colorectal cancer, advanced or metastatic gastric cancer, advanced or relapsed/refractory Hepatocellular carcinoma, metastatic non-small cell lung cancer.

How does this medication work?

CYRAMZA (Ramucirumab) is a recombinant monoclonal antibody which inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with high affinity.  When bound, it blocks receptor ligands VEGF-A, VEGF-C, and VEGF-D to inhibit activation of VEGFR2.  VEGFR2 blockage results in inhibiting ligand-induced proliferation and migration of endothelial cells, reduced tumor vascularity and growth.

How should I take this medication? 

IV: Inject 8-10 mg/kg by intravenous infusion once every 2 weeks as a single agent, or in combination with appropriate agents depending on indication it is being used for.  Continue Ramucirumab until disease progression or unacceptable toxicity.

How to Take: Do not administer as an IV push or bolus. Administer initial infusion over 60 minutes and if tolerated you may administer subsequent infusions over 30 minutes.  The the use of a 0.22-micron protein-sparing filter is recommended. Flush the line with NS after infusion is complete. Monitor for infusion reaction.  Reduce infusion rate (by 50%) for grade 1 or 2 infusion reaction and discontinue permanently for grade 3 or 4 infusion reaction. 

What should I watch for while using this medication? 

Before starting CYRAMZA (Ramucirumab), make sure your physician is aware of any allergies or medications you currently take, if you are pregnant, or breastfeeding. Ramucirumab use has been associated with rare but serious adverse events such as arterial thrombotic events, bone marrow suppression, gastrointestinal perforation, hemorrhage, hepatotoxicity, hypertension, infusion reactions, posterior reversible encephalopathy syndrome, proteinuria, nephrotic syndrome, thyroid dysfunction, and wound healing impairment.

What if I miss a dose?

If you miss an infusion, contact your doctor immediately for further instructions.

How should I store this medication?

Store intact vials at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake. Solutions diluted for infusion may be stored at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours (do not freeze) or may be stored for 4 hours at room temperature (below 25°C [77°F]); do not shake diluted product.

What are the possible side effects of using this medication?

Hypertension, peripheral edema, hypoalbuminemia, hypocalcemia, hyponatremia, abdominal pain, decreased appetite, diarrhea, nausea, proteinuria, neutropenia, thrombocytopenia, ascites, fatigue, headache, insomnia, epistaxis.

Note this is not a complete list of side effects for CYRAMZA (Ramucirumab), only common ones.